| Food-Safety Head Steps Down The Food and Drug Administration's director of food safety is leaving for an academic post. online.wsj.com |
Stock Alert for Cord Blood America Inc. Issued by MicroStockProfit (GlobeNewswire) DALLAS -- MicroStockProfit.com announces an investment report featuring Cord Blood America Inc. . The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision. us.rd.yahoo.com |
Group Eases Limits on Births After C-Sections Updated guidelines from an influential physician group may make it easier for women to give birth vaginally after a cesarean. online.wsj.com |
GSK's Diabetes Drug Continues to Face Scrutiny: Biotech's Latest Mishaps The Burrill Report submits: GlaxoSmithKline’s (GSK) diabetes drug Avandia is once again under regulatory scrutiny—this time it’s in Europe where the European Medicines Agency met to discuss whether Avandia should continue to be marketed. The agency in a press statement said that no final decision has been made about the drug. It said it has further questions for GSK before deciding whether and what action needs to be taken. A final decision is expected by September 23. The meeting took place as a controversy erupted in the United Kingdom over a recommendation made at the end of July by the UK Commission on Human Medicines, according to TheHeart.Org. The commission unanimously voted that Avandia should be withdrawn. Though it informed the Medicines and Healthcare Products Regulatory Agency, the agency responsible for licensing drugs in the United Kingdom, its decision was not made public. Instead the agency sent letters to doctors restating safety information about the drug and suggesting they consider alternatives. Because the drug was approved by the European Medicines Agency, only it can revoke the license for the drug. Roche (RHHBY.PK) said it halted dosing of patients in a late-stage trial of its experimental diabetes drug taspoglutide because side effects including nausea and vomiting resulted in many participants in the study to drop out of it, Bloomberg reported. The company is trying to determine what caused the side effects and see if it can reformulate the medication to reduce the risk, a spokeswoman told Bloomberg. Because a large number of patients dropped out of the study, the company said it would be difficult to determine whether the drug is effective.Complete Story » seekingalpha.com |
Dialysis for the Busy Patient For most, kidney dialysis means sitting in a hospital hooked up to a machine for hours, three days a week. Although doing dialysis at home offers advantages, few patients have chosen to go this route. online.wsj.com |